Zimbabwe has turned down a significant US healthcare agreement worth 367 million US dollars (£272m) over five years due to the United States' demand for confidential biological samples.
The decision was revealed after a official document dated December was leaked, which showed President Emmerson Mnangagwa believed the agreement was "skewed".
A government spokesman later stated that the United States was seeking genetic material for scientific study and profit but refused to share the benefits from any future treatments.
"We will now turn to the difficult and regrettable task of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged continued talks to reach a deal suitable to all parties so the country's critical HIV treatment initiative can continue.
Wider Background
Zimbabwe's decision comes after a comparable situation in Kenya, where a high court halted a related deal with the US following legal challenges were raised about the security of citizens' health data.
After resuming office last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had managed aid for the American government, but Trump argued its expenditure was "wasteful" and his administration was pursuing government-to-government deals to boost openness and responsibility.
According to statements, Sixteen African countries have to date agreed to these new agreements, constituting over $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership might have yielded immense advantages for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment through American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"Our nation was requested to provide its biological resources and data indefinitely, without any corresponding promise of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," he stated.
"Effectively, our nation would provide the basic resources for scientific discovery without any certainty that the end products would be accessible to our population should a future pandemic emerge."
National Interest and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were undermining structures already established via the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with potential global health emergencies.
"This mechanism is designed to ensure that when a country contributes its samples, the benefits – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
These objections regarding the US deal "are not meant as opposition to America," he added.
"We encourage continued discussions with our US partners on how subsequent collaboration could be arranged in a manner that respects the independence and dignity of each country."
Health Experts Reaction
A leading public health body said it acknowledged the government's concerns, but urged that negotiations should continue given that much of the nation's Aids initiatives relied on international support.
"If specific concerns exist, including those involving data governance or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," the group said.
The situation emphasises the continuing debate between accepting much-needed foreign assistance and safeguarding a country's data in an ever more interconnected world.